Rheumatoid Arthritis Clinical Trial
— DOSEOfficial title:
Drug Outcome Survey for Biological Treatments in Rheumatoid Arthritis: an Observational Study
NCT number | NCT00794118 |
Other study ID # | 0881A1-102321 |
Secondary ID | B1801119 |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 2008 |
Est. completion date | April 2011 |
Verified date | June 2019 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary purpose of this observational study is to describe and define the current daily practice of management of anti-TNF-agents in Rheumatoid Arthritis (RA) patients. Data will be collected only from subjects providing informed consent.
Status | Completed |
Enrollment | 299 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Eighteen years of age or older 2. Diagnosis of RA in accordance with ARA 1987 classification has satisfied at least 4 of the following 7 criteria: 1. Morning stiffness in and around the joints lasting at least 1 hour; 2. Arthritis of 3 or more joint areas; 3. Arthritis of hand joints; 4. Symmetric arthritis. simultaneous involvement of the same joint areas on both sides of the body; 5. Rheumatoid nodules; 6. Serum Rheumatoid Factor (RF) 7. Radiographic changes. Criteria 1 through 4 must have been present for at least 6 weeks. 3. Patients refractory or without complete response to DMARDs according to the Italian Guidelines for the clinical practice established by Italian Society of Rheumatology 4. Patients naive to anti-TNF drugs 5. Outpatients Exclusion Criteria: Patients involved in controlled or interventional trials in the 12 previous months |
Country | Name | City | State |
---|---|---|---|
Italy | Pfizer Investigational Site | Roma |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 3 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (<=) 3.2 = low disease activity, DAS28 greater than (>) 3.2 to 5.1 = moderate to high disease activity. A participant is considered to be in remission if they have a DAS28 less than (<) 2.6. | Month 3 | |
Primary | Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 6 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. A participant is considered to be in remission if they have a DAS28 <2.6. | Month 6 | |
Primary | Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 9 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. A participant is considered to be in remission if they have a DAS28 <2.6. | Month 9 | |
Primary | Percentage of Participants With Disease Activity Score Based on 28-joints Count (DAS28) Remission at Month 12 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. A participant is considered to be in remission if they have a DAS28 < 2.6. | Month 12 | |
Primary | Disease Activity Score Based on 28-joints Count (DAS28) at Month 3 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | Month 3 | |
Primary | Disease Activity Score Based on 28-joints Count (DAS28) at Month 6 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | Month 6 | |
Primary | Disease Activity Score Based on 28-joints Count (DAS28) at Month 9 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | Month 9 | |
Primary | Disease Activity Score Based on 28-joints Count (DAS28) at Month 12 | DAS28 calculated from the SJC and PJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 <=3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | Month 12 | |
Primary | Patient Global Assessment (PtGA) of Disease Activity Score at Month 3 | PtGA measured using a 10 cm (VAS) ranging from 0 cm = very good to 10 cm = very bad. | Month 3 | |
Primary | Patient Global Assessment (PtGA) of Disease Activity Score at Month 6 | PtGA measured using a 10 cm (VAS) ranging from 0 cm = very good to 10 cm = very bad. | Month 6 | |
Primary | Patient Global Assessment (PtGA) of Disease Activity Score at Month 9 | PtGA measured using a 10 cm (VAS) ranging from 0 cm = very good to 10 cm = very bad. | Month 9 | |
Primary | Patient Global Assessment (PtGA) of Disease Activity Score at Month 12 | PtGA measured using a 10 cm (VAS) ranging from 0 cm = very good to 10 cm = very bad. | Month 12 | |
Primary | Physician Global Assessment (PGA) of Disease Activity at Month 3 | PGA was measured on a 0 to 10 cm VAS, with 0 cm = no disease activity to 10 cm = worst disease activity possible. | Month 3 | |
Primary | Physician Global Assessment (PGA) of Disease Activity at Month 6 | PGA was measured on a 0 to 10 cm VAS, with 0 cm = no disease activity to 10 cm = worst disease activity possible. | Month 6 | |
Primary | Physician Global Assessment (PGA) of Disease Activity at Month 9 | PGA was measured on a 0 to 10 cm VAS, with 0 cm = no disease activity to 10 cm = worst disease activity possible. | Month 9 | |
Primary | Physician Global Assessment (PGA) of Disease Activity at Month 12 | PGA was measured on a 0 to 10 cm VAS, with 0 cm = no disease activity to 10 cm = worst disease activity possible. | Month 12 | |
Primary | Visual Analogue Scale for Pain (VAS-pain) at Month 3 | 10 cm line (VAS) marked by participant. Intensity of pain range 0 cm = no pain to 10 cm = worst possible pain. | Month 3 | |
Primary | Visual Analogue Scale for Pain (VAS-pain) at Month 6 | 10 cm line (VAS) marked by participant. Intensity of pain range 0 cm = no pain to 10 cm = worst possible pain. | Month 6 | |
Primary | Visual Analogue Scale for Pain (VAS-pain) at Month 9 | 10 cm line (VAS) marked by participant. Intensity of pain range 0 cm = no pain to 10 cm = worst possible pain. | Month 9 | |
Primary | Visual Analogue Scale for Pain (VAS-pain) at Month 12 | 10 cm line (VAS) marked by participant. Intensity of pain range 0 cm = no pain to 10 cm = worst possible pain. | Month 12 | |
Primary | C-reactive Protein (CRP) at Month 3 | CRP is a marker of inflammation. CRP value higher than 0.5 mg/dL is consistent with inflammation. | Month 3 | |
Primary | C-reactive Protein (CRP) at Month 6 | CRP is a marker of inflammation. CRP value higher than 0.5 mg/dL is consistent with inflammation. | Month 6 | |
Primary | C-reactive Protein (CRP) at Month 9 | CRP is a marker of inflammation. CRP value higher than 0.5 mg/dL is consistent with inflammation. | Month 9 | |
Primary | C-reactive Protein (CRP) at Month 12 | CRP is a marker of inflammation. CRP value higher than 0.5 mg/dL is consistent with inflammation. | Month 12 | |
Primary | Erythrocyte Sedimentation Rate (ESR) at Month 3 | ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation. | Month 3 | |
Primary | Erythrocyte Sedimentation Rate (ESR) at Month 6 | ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation. | Month 6 | |
Primary | Erythrocyte Sedimentation Rate (ESR) at Month 9 | ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation. | Month 9 | |
Primary | Erythrocyte Sedimentation Rate (ESR) at Month 12 | ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation. | Month 12 | |
Primary | Number of Participants With Rheumatoid Factor (RF) at Month 3 | RF is the auto antibody directed against IgG and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive. | Month 3 | |
Primary | Number of Participants With Rheumatoid Factor (RF) at Month 6 | RF is the auto antibody directed against IgG and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive. | Month 6 | |
Primary | Number of Participants With Rheumatoid Factor (RF) at Month 9 | RF is the auto antibody directed against IgG and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive. | Month 9 | |
Primary | Number of Participants With Rheumatoid Factor (RF) at Month 12 | RF is the auto antibody directed against IgG and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive. | Month 12 | |
Primary | Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 3 | Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive. | Month 3 | |
Primary | Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 6 | Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive. | Month 6 | |
Primary | Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 9 | Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive. | Month 9 | |
Primary | Number of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at Month 12 | Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants. Anti-CCP antibodies value higher than 10 U/mL is considered positive. | Month 12 | |
Primary | Number of Participants With Anti-nuclear Antibodies at Month 3 | Anti-nuclear antibodies are auto antibodies directed against contents of the nucleus and are present in higher than normal numbers in autoimmune disease. Anti-nuclear antibodies value higher than 1:160 is considered positive. | Month 3 | |
Primary | Number of Participants With Anti-nuclear Antibodies at Month 6 | Anti-nuclear antibodies are auto antibodies directed against contents of the nucleus and are present in higher than normal numbers in autoimmune disease. Anti-nuclear antibodies value higher than 1:160 is considered positive. | Month 6 | |
Primary | Number of Participants With Anti-nuclear Antibodies at Month 9 | Anti-nuclear antibodies are auto antibodies directed against contents of the nucleus and are present in higher than normal numbers in autoimmune disease. Anti-nuclear antibodies value higher than 1:160 is considered positive. | Month 9 | |
Primary | Number of Participants With Anti-nuclear Antibodies at Month 12 | Anti-nuclear antibodies are auto antibodies directed against contents of the nucleus and are present in higher than normal numbers in autoimmune disease. Anti-nuclear antibodies value higher than 1:160 is considered positive. | Month 12 | |
Primary | Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 3 | Anti-DNA antibodies are auto antibodies directed against DNA and are present in higher than normal numbers in autoimmune disease. Anti-DNA antibodies value higher than 1:20 is considered positive. | Month 3 | |
Primary | Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 6 | Anti-DNA antibodies are auto antibodies directed against DNA and are present in higher than normal numbers in autoimmune disease. Anti-DNA antibodies value higher than 1:20 is considered positive. | Month 6 | |
Primary | Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 9 | Anti-DNA antibodies are auto antibodies directed against DNA and are present in higher than normal numbers in autoimmune disease. Anti-DNA antibodies value higher than 1:20 is considered positive. | Month 9 | |
Primary | Number of Participants With Anti-deoxyribonucleic Acid (Anti-DNA) Antibodies at Month 12 | Anti-DNA antibodies are auto antibodies directed against DNA and are present in higher than normal numbers in autoimmune disease. Anti-DNA antibodies value higher than 1:20 is considered positive. | Month 12 | |
Primary | Duration of Morning Stiffness at Month 3 | Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. | Month 3 | |
Primary | Duration of Morning Stiffness at Month 6 | Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. | Month 6 | |
Primary | Duration of Morning Stiffness at Month 9 | Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. | Month 9 | |
Primary | Duration of Morning Stiffness at Month 12 | Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement. | Month 12 | |
Primary | Stanford Health Assessment Questionnaire (HAQ) Score at Month 3 | HAQ is a measure of functional limitations. Participants were rated on 4 point scale with scores: 0=no difficulty (normal), 1=some difficulty (adequate), 2=much difficulty (limited), 3=unable to do based on degree of difficulty experienced with 20 tasks grouped into 8 areas of dressing, rising, hygiene, reach, walking, eating, grip and activities. The higher score reported by the participant for any component question of the 8 categories determines the score for that categories. Total score is divided for 8. Average score range: 0 (no difficulty) to 3 (unable to do). | Month 3 | |
Primary | Stanford Health Assessment Questionnaire (HAQ) Score at Month 6 | HAQ is a measure of functional limitations. Participants were rated on 4 point scale with scores: 0=no difficulty (normal), 1=some difficulty (adequate), 2=much difficulty (limited), 3=unable to do based on degree of difficulty experienced with 20 tasks grouped into 8 areas of dressing, rising, hygiene, reach, walking, eating, grip and activities. The higher score reported by the participant for any component question of the 8 categories determines the score for that categories. Total score is divided for 8. Average score range: 0 (no difficulty) to 3 (unable to do). | Month 6 | |
Primary | Stanford Health Assessment Questionnaire (HAQ) Score at Month 9 | HAQ is a measure of functional limitations. Participants were rated on 4 point scale with scores: 0=no difficulty (normal), 1=some difficulty (adequate), 2=much difficulty (limited), 3=unable to do based on degree of difficulty experienced with 20 tasks grouped into 8 areas of dressing, rising, hygiene, reach, walking, eating, grip and activities. The higher score reported by the participant for any component question of the 8 categories determines the score for that categories. Total score is divided for 8. Average score range: 0 (no difficulty) to 3 (unable to do). | Month 9 | |
Primary | Stanford Health Assessment Questionnaire (HAQ) Score at Month 12 | HAQ is a measure of functional limitations. Participants were rated on 4 point scale with scores: 0=no difficulty (normal), 1=some difficulty (adequate), 2=much difficulty (limited), 3=unable to do based on degree of difficulty experienced with 20 tasks grouped into 8 areas of dressing, rising, hygiene, reach, walking, eating, grip and activities. The higher score reported by the participant for any component question of the 8 categories determines the score for that categories. Total score is divided for 8. Average score range: 0 (no difficulty) to 3 (unable to do). | Month 12 | |
Primary | 36-Item Short-Form Health Survey (SF-36) at Month 12 | SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). | Month 12 | |
Secondary | Direct Costs | Direct costs included all expenses requiring actual payment or time spent due to the disease itself or to disability. | Baseline, Months 3, 6, 9 and 12 | |
Secondary | Indirect Costs | Indirect costs represent the loss of resources as a consequence of work disability or unemployment. | Baseline, Months 3, 6, 9 and 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |